Klaus is an accomplished life science professional with more than 20 years experience in international business development, product and technology licensing as well as discovery research in academia, biotech and pharmaceutical industry. Klaus joined AbbVie’s Search and Evaluation group in August 2016. Prior to AbbVie he was BD consultant for iTeos Therapeutics and Rigel Pharmaceuticals, Licensing Director for Oncology within Amgen’s External R&D group and had a similar role in R&D Licensing at Boehringer Ingelheim in Germany. His academic research career included positions at the Max-Planck Institute in Munich, the Salk Institute in La Jolla, and the EMBL and the Cancer Research Center in Heidelberg. Klaus holds a Ph.D. from the University of Heidelberg, Germany.